Patent: 9,925,151
✉ Email this page to a colleague
Summary for Patent: 9,925,151
Title: | Cladribine regimen for treating multiple sclerosis |
Abstract: | The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy. |
Inventor(s): | Brentzel, Jr.; H. James (Marshfield, MA), Lopez-Bresnahan; Maria (Lincoln, MA), Ammoury; Nazih (Prevessin-Moens, FR) |
Assignee: | MERCK SERONO SA (Coinsins, Vaud, CH) |
Application Number: | 12/301,083 |
Patent Claims: | see list of patent claims |
Details for Patent 9,925,151
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bayer Healthcare Pharmaceuticals Inc. | BETASERON | interferon beta-1b | For Injection | 103471 | 07/23/1993 | ⤷ Try a Trial | 2026-05-24 |
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | ⤷ Try a Trial | 2026-05-24 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 05/28/2003 | ⤷ Try a Trial | 2026-05-24 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 02/27/2012 | ⤷ Try a Trial | 2026-05-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |